These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. Filion KB; Azoulay L; Platt RW; Dahl M; Dormuth CR; Clemens KK; Hu N; Paterson JM; Targownik L; Turin TC; Udell JA; Ernst P; N Engl J Med; 2016 Mar; 374(12):1145-54. PubMed ID: 27007958 [TBL] [Abstract][Full Text] [Related]
8. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. Wanner C; Inzucchi SE; Lachin JM; Fitchett D; von Eynatten M; Mattheus M; Johansen OE; Woerle HJ; Broedl UC; Zinman B; N Engl J Med; 2016 Jul; 375(4):323-34. PubMed ID: 27299675 [TBL] [Abstract][Full Text] [Related]
9. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso SP; Daniels GH; Brown-Frandsen K; Kristensen P; Mann JF; Nauck MA; Nissen SE; Pocock S; Poulter NR; Ravn LS; Steinberg WM; Stockner M; Zinman B; Bergenstal RM; Buse JB; ; N Engl J Med; 2016 Jul; 375(4):311-22. PubMed ID: 27295427 [TBL] [Abstract][Full Text] [Related]
10. Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study). Aroda VR; Bailey TS; Cariou B; Kumar S; Leiter LA; Raskin P; Zacho J; Andersen TH; Philis-Tsimikas A Diabetes Obes Metab; 2016 Jul; 18(7):663-70. PubMed ID: 26990378 [TBL] [Abstract][Full Text] [Related]
11. Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials. Wang T; Wang F; Zhou J; Tang H; Giovenale S Diabetes Metab Res Rev; 2016 Nov; 32(8):843-857. PubMed ID: 27037787 [TBL] [Abstract][Full Text] [Related]
12. Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes. El Bekay R; Coín-Aragüez L; Fernández-García D; Oliva-Olivera W; Bernal-López R; Clemente-Postigo M; Delgado-Lista J; Diaz-Ruiz A; Guzman-Ruiz R; Vázquez-Martínez R; Lhamyani S; Roca-Rodríguez MM; Veledo SF; Vendrell J; Malagón MM; Tinahones FJ Br J Pharmacol; 2016 Jun; 173(11):1820-34. PubMed ID: 26993859 [TBL] [Abstract][Full Text] [Related]
13. Glucagon-like peptide-1 and vitamin D: anti-inflammatory response in diabetic kidney disease in db/db mice and in cultured endothelial cells. Einbinder Y; Ohana M; Benchetrit S; Zehavi T; Nacasch N; Bernheim J; Zitman-Gal T Diabetes Metab Res Rev; 2016 Nov; 32(8):805-815. PubMed ID: 26991522 [TBL] [Abstract][Full Text] [Related]
14. Effect of Liraglutide on Corneal Kindling Epilepsy Induced Depression and Cognitive Impairment in Mice. Koshal P; Kumar P Neurochem Res; 2016 Jul; 41(7):1741-50. PubMed ID: 27017512 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Outcome Studies in Diabetes: How Do We Make Sense of These New Data? Strain WD; Smith C Diabetes Ther; 2016 Jun; 7(2):175-85. PubMed ID: 27010644 [TBL] [Abstract][Full Text] [Related]
16. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Tonneijck L; Smits MM; Muskiet MHA; Hoekstra T; Kramer MHH; Danser AHJ; Diamant M; Joles JA; van Raalte DH Diabetologia; 2016 Jul; 59(7):1412-1421. PubMed ID: 27038451 [TBL] [Abstract][Full Text] [Related]
17. Incretin hormone receptors are required for normal beta cell development and function in female mice. Omar B; Ahlkvist L; Yamada Y; Seino Y; Ahrén B Peptides; 2016 May; 79():58-65. PubMed ID: 27020250 [TBL] [Abstract][Full Text] [Related]
18. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects against amyloid-β peptide-induced impairment of spatial learning and memory in rats. Jia XT; Ye-Tian ; Yuan-Li ; Zhang GJ; Liu ZQ; Di ZL; Ying XP; Fang Y; Song EF; Qi JS; Pan YF Physiol Behav; 2016 May; 159():72-9. PubMed ID: 26992957 [TBL] [Abstract][Full Text] [Related]